Tvardi Therapeutics(DE:69C)
€1.17+0.25 (+63.64%)
DE:69C
Tvardi Therapeutics financials statements
€1.17
At close:+0.25 (+63.64%)
Tvardi Therapeutics (69C) Ratios
1 Followers
Tvardi Therapeutics Ratios
DE:69C's free cash flow for Q2 2026 was $-9.23M. For the 2026 fiscal year, DE:69C's free cash flow was increased by $0.00 and operating cash flow was $-9.23M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.86 | 11.03 | 7.97 | 10.31 | 9.84 |
| Quick Ratio | 2.86 | 10.81 | 7.97 | 10.31 | 9.69 |
| Cash Ratio | 1.88 | 9.54 | 6.99 | 5.02 | 0.76 |
| Solvency Ratio | -1.63 | -1.46 | -1.33 | -0.93 | -4.45 |
| Operating Cash Flow Ratio | -2.13 | -15.34 | -6.41 | -4.18 | -3.41 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -9.31 | -34.24 |
| Net Current Asset Value | $ 20.41M | $ -4.59M | $ -62.90M | $ -46.04M | $ 153.76M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 1.01 | 0.01 | 0.05 | 0.01 |
| Debt-to-Equity Ratio | 0.01 | -9.68 | -0.01 | -0.05 | 0.02 |
| Debt-to-Capital Ratio | 0.01 | 1.12 | -0.01 | -0.06 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 1.12 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.53 | -9.54 | -0.44 | -1.00 | 1.09 |
| Debt Service Coverage Ratio | 0.00 | -7.34 | 0.00 | -43.63 | -49.51 |
| Interest Coverage Ratio | 0.00 | -6.58 | 0.00 | -29178.33 | 0.00 |
| Debt to Market Cap | 0.00 | 5.96 | 0.00 | 0.04 | 0.25 |
| Interest Debt Per Share | 0.03 | 34.80 | 0.04 | 0.25 | 2.61 |
| Net Debt to EBITDA | 1.13 | -0.10 | 0.19 | 0.23 | 0.11 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 88.62% | 69.32% | 82.05% | 93.25% |
| EBIT Margin | 0.00% | -879.81% | -562.33% | -204.16% | -384.06% |
| EBITDA Margin | 0.00% | -877.12% | -561.09% | -200.17% | -377.31% |
| Operating Profit Margin | 0.00% | -781.57% | -579.43% | -209.08% | -386.85% |
| Pretax Profit Margin | 0.00% | -998.53% | -565.21% | -204.16% | -384.06% |
| Net Profit Margin | 0.00% | -992.95% | -565.21% | -204.16% | -384.06% |
| Continuous Operations Profit Margin | 0.00% | -992.95% | -565.21% | -204.16% | -384.06% |
| Net Income Per EBT | 100.00% | 99.44% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 68.09% | 127.76% | 97.55% | 97.65% | 99.28% |
| Return on Assets (ROA) | -56.79% | -161.70% | -438.92% | -189.53% | -35.80% |
| Return on Equity (ROE) | -86.96% | 1542.93% | 190.97% | 189.73% | -38.87% |
| Return on Capital Employed (ROCE) | -127.18% | -139.96% | -512.20% | -214.44% | -38.83% |
| Return on Invested Capital (ROIC) | -126.49% | -139.18% | -510.20% | -204.43% | -38.53% |
| Return on Tangible Assets | -57.37% | -161.70% | -446.33% | -191.71% | -35.80% |
| Earnings Yield | -57.09% | -950.92% | -258.52% | -186.45% | -1281.13% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 1.59 | 5.22 | 9.40 | 19.99 |
| Payables Turnover | 0.03 | 0.57 | 3.99 | 3.12 | 0.28 |
| Inventory Turnover | 0.00 | 0.90 | 0.00 | 0.00 | 0.60 |
| Fixed Asset Turnover | 0.00 | 0.00 | 55.47 | 91.02 | 6.39 |
| Asset Turnover | 0.00 | 0.16 | 0.78 | 0.93 | 0.09 |
| Working Capital Turnover Ratio | 0.00 | 0.23 | 0.67 | 0.43 | 0.14 |
| Cash Conversion Cycle | -12367.74 | -10.15 | -21.48 | -78.20 | -696.00 |
| Days of Sales Outstanding | 0.00 | 229.88 | 69.93 | 38.82 | 18.26 |
| Days of Inventory Outstanding | 0.00 | 404.56 | 0.00 | 0.00 | 606.92 |
| Days of Payables Outstanding | 12367.74 | 644.59 | 91.41 | 117.02 | 1321.19 |
| Operating Cycle | 0.00 | 634.44 | 69.93 | 38.82 | 625.18 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.17 | -40.05 | -2.25 | -1.91 | -42.65 |
| Free Cash Flow Per Share | -3.17 | -40.74 | -2.25 | -1.92 | -42.68 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -58.24 | -8.86 | -357.32 | -1540.69 |
| Capital Expenditure Coverage Ratio | 0.00 | -58.24 | -8.86 | -357.32 | -1540.69 |
| Operating Cash Flow Coverage Ratio | -116.91 | -1.37 | -57.17 | -7.54 | -16.36 |
| Operating Cash Flow to Sales Ratio | 0.00 | -8.54 | -1.00 | -0.43 | -2.61 |
| Free Cash Flow Yield | -73.66% | -831.44% | -45.90% | -39.08% | -870.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.75 | -0.11 | -0.39 | -0.54 | -0.08 |
| Price-to-Sales (P/S) Ratio | 0.00 | 1.04 | 2.19 | 1.09 | 0.30 |
| Price-to-Book (P/B) Ratio | 1.52 | -1.62 | -0.74 | -1.02 | 0.03 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.36 | -0.12 | -2.18 | -2.56 | -0.11 |
| Price-to-Operating Cash Flow Ratio | -1.36 | -0.12 | -2.18 | -2.57 | -0.11 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | -0.00 | 0.02 | 0.01 | 0.00 |
| Enterprise Value Multiple | -0.63 | -0.22 | -0.20 | -0.32 | 0.03 |
| Enterprise Value | 11.37M | 14.00M | 23.29M | 26.72M | -2.88M |
| EV to EBITDA | -0.63 | -0.22 | -0.20 | -0.32 | 0.03 |
| EV to Sales | 0.00 | 1.96 | 1.11 | 0.64 | -0.12 |
| EV to Free Cash Flow | -0.48 | -0.23 | -1.11 | -1.49 | 0.05 |
| EV to Operating Cash Flow | -0.48 | -0.23 | -1.11 | -1.50 | 0.05 |
| Tangible Book Value Per Share | 2.78 | -3.02 | -6.68 | -4.87 | 161.49 |
| Shareholders’ Equity Per Share | 2.82 | -3.02 | -6.63 | -4.82 | 161.49 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 4.69 | 2.24 | 4.48 | 16.35 |
| Net Income Per Share | -2.46 | -46.60 | -12.67 | -9.14 | -62.78 |
| Tax Burden | 1.00 | 0.99 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.13 | 1.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 4.59 | 5.17 | 2.19 | 3.59 |
| SG&A to Revenue | 0.00 | 3.70 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Income Quality | 1.29 | 0.86 | 1.21 | 0.87 | 0.68 |
Currency in USD
